Tumours derived from chronic IFNγ-pre-treated YUMM2.1 cells exhibited a significantly lower percentage of T cells (TCRαβ+) and a higher percentage of regulatory T (Treg) cells (Foxp3+, CD25high) relative to tumours derived from either IFNγ-naïve cells but also to shPARP14-expressing IFNγ-pre-treated YUMM2.1 cells (Fig. 5G–J), implying that PARP14 might contribute to the immunosuppressive tumour microenvironment induced by chronic IFNγ pre-treatment. The gene discussed is IFNG; the disease is neoplasm.